AUA: Post-marketing studies of ED therapies are under review

The latest update of AUA guidelines for management of organic erectile dysfunction will focus on novel treatment recommendations and suggestions for study designs that minimize conflicts of interest in post-marketing comparisons of oral drug therapies.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria